(19)
(11) EP 3 013 946 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
10.04.2019 Bulletin 2019/15

(45) Mention of the grant of the patent:
06.02.2019 Bulletin 2019/06

(21) Application number: 14733199.5

(22) Date of filing: 27.06.2014
(51) International Patent Classification (IPC): 
C12N 7/00(2006.01)
 C07K 14/47(2006.01)
(86) International application number:
PCT/EP2014/063676
(87) International publication number:
WO 2014/207190 (31.12.2014 Gazette 2014/53)

(54)

METHODS FOR EXPRESSING A POLYNUCLEOTIDE OF INTEREST IN THE RETINA OF A SUBJECT

VERFAHREN ZUR EXPRESSION VON EINES POLYNUCLEOTIDS VON INTERESSE IN DER NETZHAUT EINER PERSON

PROCÉDÉS POUR L'EXPRESSION D'UN POLYNUCLÉOTIDE D'INTÉRÊT DANS LA RÉTINE D'UN SUJET

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 28.06.2013 EP 13305914

(43) Date of publication of application:
04.05.2016 Bulletin 2016/18

(73) Proprietors:
  • INSERM (Institut National de la Santé et de la Recherche Médicale)
    75013 Paris (FR)
  • Sorbonne Université
    75006 Paris (FR)
  • Centre National de la Recherche Scientifique (C.N.R.S.)
    75016 Paris (FR)

(72) Inventors:
  • DALKARA, Deniz
    F-75012 Paris (FR)
  • RENDON FUENTES, Alvaro
    F-75012 Paris (FR)
  • SAHEL, José Alain
    F-75012 Paris (FR)
  • VACCA, Ophélie
    F-75012 Paris (FR)

(74) Representative: Inserm Transfert 
7, rue Watt
75013 Paris
75013 Paris (FR)


(56) References cited: : 
WO-A1-2010/149765
WO-A2-2010/011404
 WO-A2-2010/000851
WO-A2-2012/145601
   
  • OPHÉLIE VACCA ET AL: "AAV-mediated gene delivery in Dp71-null mouse model with compromised barriers", GLIA, vol. 62, no. 3, 31 March 2014 (2014-03-31) , pages 468-476, XP055141047, ISSN: 0894-1491, DOI: 10.1002/glia.22617
  • FORT P ET AL: "DYSTROPHIN PROTEIN DP71 AND RETINA: A NEW PHENOTYPE", ARVO ANNUAL MEETING ABSTRACT SEARCH AND PROGRAM PLANNER, XX, XX, vol. 2002, 5 May 2002 (2002-05-05), page 661, XP009085268,
  • BRINGMANN A ET AL: "Muller cells in the healthy and diseased retina", PROGRESS IN RETINAL AND EYE RESEARCH, OXFORD, GB, vol. 25, no. 4, 1 July 2006 (2006-07-01), pages 397-424, XP028074816, ISSN: 1350-9462, DOI: 10.1016/J.PRETEYERES.2006.05.003 [retrieved on 2006-07-01]
  • BERMUDEZ DE LEON M ET AL: "beta-naphthoflavone represses dystrophin Dp71 expression in Hepa-1 cells", BIOCHIMICA ET BIOPHYSICA ACTA . GENE STRUCTURE AND EXPRESSION, ELSEVIER, AMSTERDAM, NL, vol. 1759, no. 3-4, 1 March 2006 (2006-03-01), pages 152-158, XP027896498, ISSN: 0167-4781 [retrieved on 2006-03-01]
  • Mario Bermúdez De León ET AL: "Dystrophin Dp71 Expression Is Down-regulated during Myogenesis : ROLE OF Sp1 AND Sp3 ON THE Dp71 PROMOTER ACTIVITY", Journal of Biological Chemistry, vol. 280, no. 7, 18 February 2005 (2005-02-18), pages 5290-5299, XP055444822, ISSN: 0021-9258, DOI: 10.1074/jbc.M411571200
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).